Nyxoah (NASDAQ:NYXH) Stock Gets Price Target Cut from Cantor Fitzgerald

Nyxoah (NASDAQ:NYXH) had its price objective decreased by Cantor Fitzgerald to $3.00 in a research note published on Tuesday, Marketbeat reports. Cantor Fitzgerald currently has an overweight rating on the stock.

A number of other equities research analysts also recently commented on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nyxoah in a research report on Wednesday, August 19th. Oppenheimer set a $4.00 price target on Nyxoah in a research note on Thursday, August 6th. Wall Street Zen lowered shares of Nyxoah from a “hold” rating to a “sell” rating in a research report on Sunday, August 9th. Piper Sandler reiterated an “overweight” rating and issued a $6.00 price objective (down from $7.00) on shares of Nyxoah in a research note on Thursday, August 6th. Finally, Robert W. Baird set a $2.31 price objective on shares of Nyxoah in a research note on Thursday, August 6th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $3.55.

Nyxoah Price Performance

NYXH opened at $0.89 on Tuesday. The company has a current ratio of 2.38, a quick ratio of 2.31 and a debt-to-equity ratio of 0.44. The company has a market cap of $34.42 million, a price-to-earnings ratio of -0.35 and a beta of 1.65. The stock has a fifty day simple moving average of $1.36 and a two-hundred day simple moving average of $2.54. Nyxoah has a 12-month low of $0.80 and a 12-month high of $5.92.

Nyxoah (NASDAQ:NYXH) last released its earnings results on Thursday, August 6th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.20). The business had revenue of $8.76 million for the quarter, compared to analysts’ expectations of $8.64 million. Nyxoah had a negative net margin of 443.16% and a negative return on equity of 178.90%. Research analysts predict that Nyxoah will post -1.46 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of NYXH. Integrated Wealth Concepts LLC purchased a new position in Nyxoah during the second quarter worth $169,000. IFP Advisors Inc increased its position in Nyxoah by 35.6% during the second quarter. IFP Advisors Inc now owns 118,426 shares of the company’s stock valued at $200,000 after acquiring an additional 31,061 shares during the last quarter. Finally, Readystate Asset Management LP purchased a new stake in shares of Nyxoah in the second quarter valued at $351,000.

Nyxoah Company Profile

Nyxoah SA is a medical technology company focused on developing and commercializing solutions for obstructive sleep apnea (OSA), a common sleep-related breathing disorder. The company is headquartered in Mont-Saint-Guibert, Belgium, and its shares trade on the Nasdaq under the symbol NYXH.

Nyxoah’s principal product is the Genio system, an implantable, rechargeable device designed to treat OSA through hypoglossal nerve stimulation. The system is intended to help maintain an open airway during sleep by stimulating the nerves that control the tongue and related upper-airway muscles.